Werewolf Therapeutics, Inc.(HOWL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

HOWL Werewolf Therapeutics, Inc.

Trading 12-22 09:57:28 EST

0.7333

+0.0465

+6.77%

High0.7399	Low0.7000	Vol118.21K
Open0.7000	D1 Closing0.6868	Amplitude5.81%
Mkt Cap35.59M	Tradable Cap25.67M	Total Shares48.54M
T/O84.73K	T/O Rate0.34%	Tradable Shares35.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"HOWL","market":"US","secType":"STK","nameCN":"Werewolf Therapeutics, Inc.","latestPrice":0.7333,"timestamp":1766415441549,"preClose":0.6868,"halted":0,"volume":118214,"delay":0,"floatShares":35002600,"shares":48540200,"eps":-1.617698,"marketStatus":"Trading","change":0.0465,"latestTime":"12-22 09:57:28 EST","open":0.7,"high":0.7399,"low":0.7,"amount":84734.7076312,"amplitude":0.058096,"askPrice":0.7399,"askSize":200,"bidPrice":0.7334,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-1.617698,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1766437200000},"marketStatusCode":2,"adr":0,"listingDate":1619755200000,"exchange":"NASDAQ","adjPreClose":0.6868,"preHourTrading":{"tag":"盘前","latestPrice":0.7,"preClose":0.6868,"latestTime":"09:26 EST","volume":12898,"amount":9310.6715212,"timestamp":1766413585447},"postHourTrading":{"tag":"盘后","latestPrice":0.6948,"preClose":0.6868,"latestTime":"19:59 EST","volume":13042,"amount":8694.2853,"timestamp":1766192392732},"volumeRatio":0.950935,"impliedVol":2.2148,"impliedVolPercentile":0.996},"requestUrl":"/m/hq/s/HOWL","defaultTab":"news","newsList":[{"id":"2592193363","title":"Wedbush Downgrades Werewolf Therapeutics to Neutral From Outperform Due to 'Forward Challenging' Path, Cuts Price Target to $1 From $3","url":"https://stock-news.laohu8.com/highlight/detail?id=2592193363","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592193363?lang=en_us&edition=fundamental","pubTime":"2025-12-19 22:57","pubTimestamp":1766156226,"startTime":"0","endTime":"0","summary":"Werewolf Therapeutics (HOWL) has an average rating of buy and mean price target of $5, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HOWL"],"gpt_icon":0},{"id":"2592162884","title":"Werewolf Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2592162884","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592162884?lang=en_us&edition=fundamental","pubTime":"2025-12-19 20:54","pubTimestamp":1766148840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/HOWL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 19, 2025 07:54 ET (12:54 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOWL"],"gpt_icon":0},{"id":"2592909514","title":"BRIEF-Werewolf Therapeutics Inc - Plans For Two Inds By Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2592909514","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592909514?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:28","pubTimestamp":1766064531,"startTime":"0","endTime":"0","summary":"BRIEF-Werewolf Therapeutics Inc - Plans For Two Inds By Mid-2027Dec 18 (Reuters) - Werewolf Therapeutics Inc HOWL.O:WEREWOLF THERAPEUTICS INC - PLANS FOR TWO INDS BY MID-2027Source text: ID:nGNX4KTn6fFurther company coverage: HOWL.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XO0NJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","HOWL"],"gpt_icon":0},{"id":"2592666906","title":"Werewolf Therapeutics Inc - Plans for Two Inds by Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2592666906","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592666906?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:05","pubTimestamp":1766063101,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XO0NJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HOWL","BK4539","BK4139"],"gpt_icon":0},{"id":"2592906823","title":"Werewolf Therapeutics Reports Promising Phase 1 Data for WTX-124 and WTX-330 in Advanced Cancer Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2592906823","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592906823?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:00","pubTimestamp":1766062852,"startTime":"0","endTime":"0","summary":"Werewolf Therapeutics Inc. announced updates on its pipeline, including new clinical data for its INDUKINE programs. Initial Phase 1b expansion arm data for WTX-124 showed a 30% overall response rate as a monotherapy in a defined subset of post-ICI advanced or metastatic cutaneous melanoma patients, with a favorable tolerability profile. Initial data from the ongoing Phase 1b/2 trial of WTX-330 demonstrated additional evidence of antitumor activity and a highly favorable tolerability profile. The company plans to provide an additional Phase 1/1b data update for WTX-124 and complete Part A of the Phase 1b/2 clinical trial for WTX-330 in the first half of 2026. Werewolf Therapeutics is also progressing its INDUCER T cell engager platform, with plans for two IND filings by mid-2027 for WTX-1011 and WTX-2022.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL7Tg6Dz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4112","IE00BGHQF748.EUR","BK4139","BK4585","SG9999014013.SGD","HOWL","LU2210149790.SGD","NDAQ","SG9999014005.SGD","LU2095319765.USD","IE00B64PRP62.GBP","SG9999014039.USD","IE00B3QW5Z07.USD","BK4588","LU2210150020.SGD","BK4539","SG9999014021.USD","LU0314104364.USD"],"gpt_icon":0},{"id":"2592941339","title":"Director Luke Evnin Reports Disposal of Werewolf Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592941339","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592941339?lang=en_us&edition=fundamental","pubTime":"2025-12-18 07:29","pubTimestamp":1766014165,"startTime":"0","endTime":"0","summary":"Luke Evnin, Director, reported a disposal of common shares of Werewolf Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 17, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDLJX0TB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Director Luke Evnin Reports Disposal of Werewolf Therapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","HOWL"],"gpt_icon":0},{"id":"2591684062","title":"Director Luke Evnin Reports Disposal of Werewolf Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2591684062","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591684062?lang=en_us&edition=fundamental","pubTime":"2025-12-13 06:32","pubTimestamp":1765578777,"startTime":"0","endTime":"0","summary":"Luke Evnin, Director of Werewolf Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL25MMkc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Director Luke Evnin Reports Disposal of Werewolf Therapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HOWL","BK4539"],"gpt_icon":0},{"id":"2590906322","title":"Director Luke Evnin Reports Sale of Werewolf Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590906322","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590906322?lang=en_us&edition=fundamental","pubTime":"2025-12-10 06:08","pubTimestamp":1765318096,"startTime":"0","endTime":"0","summary":"Luke Evnin, a director of Werewolf Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 09, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL29hzcm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Director Luke Evnin Reports Sale of Werewolf Therapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","HOWL"],"gpt_icon":0},{"id":"2589853241","title":"MPM BioVentures 2014, L.P. Reports Disposal of Werewolf Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2589853241","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589853241?lang=en_us&edition=fundamental","pubTime":"2025-12-05 07:20","pubTimestamp":1764890427,"startTime":"0","endTime":"0","summary":"MPM BioVentures 2014, L.P. has reported a disposal of common shares of Werewolf Therapeutics Inc. The Form 4 was filed by multiple reporting persons, including MPM BioVentures 2014, L.P., MPM BioVentures 2014 , L.P., and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 04, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL6GPKqN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","HOWL"],"gpt_icon":0},{"id":"2589489853","title":"Former 10% Owner Ansbert Gadicke Reports Sale of Werewolf Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2589489853","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589489853?lang=en_us&edition=fundamental","pubTime":"2025-12-05 07:19","pubTimestamp":1764890369,"startTime":"0","endTime":"0","summary":"Ansbert Gadicke, former 10% owner, reported a disposal of common shares of Werewolf Therapeutics Inc. . Other reporting beneficial owners include MPM Oncology Innovations Fund LP, UBS Oncology Impact Fund L.P., and Oncology Impact Fund  Management L.P., among other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 04, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL7Mj8sD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Former 10% Owner Ansbert Gadicke Reports Sale of Werewolf Therapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","HOWL"],"gpt_icon":0},{"id":"2588370936","title":"Director Luke Evnin Reports Disposal of Werewolf Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588370936","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588370936?lang=en_us&edition=fundamental","pubTime":"2025-12-02 07:14","pubTimestamp":1764630852,"startTime":"0","endTime":"0","summary":"Luke Evnin, Director, reported a disposal of common shares of Werewolf Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 01, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL7ws600:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOWL","BK4139","BK4539"],"gpt_icon":0},{"id":"2588770935","title":"MPM BioVentures 2014 L.P. Reports Disposal of Werewolf Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588770935","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588770935?lang=en_us&edition=fundamental","pubTime":"2025-12-02 07:13","pubTimestamp":1764630803,"startTime":"0","endTime":"0","summary":"MPM BioVentures 2014, L.P. reported a disposal of common shares of Werewolf Therapeutics Inc. The filing was submitted by MPM BioVentures 2014, L.P., MPM BioVentures 2014 , L.P., MPM BioVentures 2014 LLC, and MPM BioVentures 2014 GP LLC, among other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 01, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL6tqxQ9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOWL","BK4139","BK4539"],"gpt_icon":0},{"id":"2588380709","title":"10% Owner Ansbert Gadicke Reports Sale of Werewolf Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588380709","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588380709?lang=en_us&edition=fundamental","pubTime":"2025-12-02 07:11","pubTimestamp":1764630707,"startTime":"0","endTime":"0","summary":"Ansbert Gadicke, a 10% owner, reported a disposal of common shares of Werewolf Therapeutics Inc. Other reporting beneficial owners include MPM Oncology Innovations Fund LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund  Management L.P., and MPM BioImpact LLC. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 01, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL6TPqxv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"10% Owner Ansbert Gadicke Reports Sale of Werewolf Therapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOWL","BK4139","BK4539"],"gpt_icon":0},{"id":"2586402762","title":"Director Luke Evnin Reports Disposal of Werewolf Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586402762","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586402762?lang=en_us&edition=fundamental","pubTime":"2025-11-26 07:05","pubTimestamp":1764111952,"startTime":"0","endTime":"0","summary":"Luke Evnin, Director at Werewolf Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 25, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL3WBS2S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOWL","BK4139","BK4539"],"gpt_icon":0},{"id":"2586027674","title":"MPM BioVentures 2014, L.P. Reports Disposal of Werewolf Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586027674","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586027674?lang=en_us&edition=fundamental","pubTime":"2025-11-26 07:05","pubTimestamp":1764111920,"startTime":"0","endTime":"0","summary":"MPM BioVentures 2014, L.P., a beneficial owner, reported a disposal of common shares of Werewolf Therapeutics Inc. The Form 4 was filed by MPM BioVentures 2014, L.P., MPM BioVentures 2014 , L.P., MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM Asset Management Investors BV2014 LLC, and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 25, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL5b9R8c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","HOWL","BK4139"],"gpt_icon":0},{"id":"2586240227","title":"10% Owner Ansbert Gadicke Reports Sale of Werewolf Therapeutics Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586240227","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586240227?lang=en_us&edition=fundamental","pubTime":"2025-11-26 07:04","pubTimestamp":1764111870,"startTime":"0","endTime":"0","summary":"Ansbert Gadicke, a 10% owner, reported a disposal of common shares of Werewolf Therapeutics Inc. . Other reporting beneficial owners include MPM Oncology Innovations Fund LP, UBS Oncology Impact Fund L.P., and Oncology Impact Fund  Management L.P., among other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 25, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL5Y2p4L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"10% Owner Ansbert Gadicke Reports Sale of Werewolf Therapeutics Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","HOWL"],"gpt_icon":0},{"id":"2584957994","title":"Werewolf Therapeutics Is Maintained at Buy by B of A Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2584957994","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584957994?lang=en_us&edition=fundamental","pubTime":"2025-11-19 02:09","pubTimestamp":1763489340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/HOWL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 18, 2025 13:09 ET (18:09 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOWL"],"gpt_icon":0},{"id":"2584603031","title":"Director Luke Evnin Reports Disposal of Werewolf Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584603031","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584603031?lang=en_us&edition=fundamental","pubTime":"2025-11-18 08:23","pubTimestamp":1763425439,"startTime":"0","endTime":"0","summary":"Luke Evnin, Director at Werewolf Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 17, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDLPlBT6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","HOWL"],"gpt_icon":0},{"id":"2584603087","title":"MPM BioVentures 2014, L.P. Reports Disposal of Werewolf Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584603087","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584603087?lang=en_us&edition=fundamental","pubTime":"2025-11-18 08:22","pubTimestamp":1763425366,"startTime":"0","endTime":"0","summary":"MPM BioVentures 2014, L.P. reported a disposal of common shares of Werewolf Therapeutics Inc. . Other reporting beneficial owners include MPM BioVentures 2014 , L.P., MPM BioVentures 2014 LLC, and MPM BioVentures 2014 GP LLC, among other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL3xMdcG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"MPM BioVentures 2014, L.P. Reports Disposal of Werewolf Therapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","HOWL"],"gpt_icon":0},{"id":"2584080603","title":"10% Owner Ansbert Gadicke Reports Disposal of Werewolf Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584080603","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584080603?lang=en_us&edition=fundamental","pubTime":"2025-11-18 08:21","pubTimestamp":1763425267,"startTime":"0","endTime":"0","summary":"Ansbert Gadicke, a 10% owner, reported a disposal of common shares of Werewolf Therapeutics Inc. The filing was made jointly with MPM Oncology Innovations Fund LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund  Management L.P., MPM BioImpact LLC, and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL2RM2YP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","HOWL"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.werewolftx.com","stockEarnings":[{"period":"1week","weight":-0.3756},{"period":"1month","weight":-0.2573},{"period":"3month","weight":-0.5391},{"period":"6month","weight":-0.4229},{"period":"1year","weight":-0.5625},{"period":"ytd","weight":-0.5359}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an IL-21 INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.205253},{"month":2,"riseRate":0.25,"avgChangeRate":-0.018207},{"month":3,"riseRate":0,"avgChangeRate":-0.190953},{"month":4,"riseRate":0.25,"avgChangeRate":-0.046509},{"month":5,"riseRate":0.4,"avgChangeRate":0.058289},{"month":6,"riseRate":0.4,"avgChangeRate":-0.083982},{"month":7,"riseRate":0.4,"avgChangeRate":0.005591},{"month":8,"riseRate":0.8,"avgChangeRate":0.038539},{"month":9,"riseRate":0.2,"avgChangeRate":0.024334},{"month":10,"riseRate":0.4,"avgChangeRate":-0.078425},{"month":11,"riseRate":0,"avgChangeRate":-0.186184},{"month":12,"riseRate":0.4,"avgChangeRate":-0.011105}],"exchange":"NASDAQ","name":"Werewolf Therapeutics, Inc.","nameEN":"Werewolf Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Werewolf Therapeutics, Inc.(HOWL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Werewolf Therapeutics, Inc.(HOWL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Werewolf Therapeutics, Inc.,HOWL,Werewolf Therapeutics, Inc.股票,Werewolf Therapeutics, Inc.股票老虎,Werewolf Therapeutics, Inc.股票老虎国际,Werewolf Therapeutics, Inc.行情,Werewolf Therapeutics, Inc.股票行情,Werewolf Therapeutics, Inc.股价,Werewolf Therapeutics, Inc.股市,Werewolf Therapeutics, Inc.股票价格,Werewolf Therapeutics, Inc.股票交易,Werewolf Therapeutics, Inc.股票购买,Werewolf Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Werewolf Therapeutics, Inc.(HOWL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Werewolf Therapeutics, Inc.(HOWL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction